WO2003035695A3 - Agents that activate or inhibit toll-like receptor 9 - Google Patents

Agents that activate or inhibit toll-like receptor 9 Download PDF

Info

Publication number
WO2003035695A3
WO2003035695A3 PCT/US2002/023645 US0223645W WO03035695A3 WO 2003035695 A3 WO2003035695 A3 WO 2003035695A3 US 0223645 W US0223645 W US 0223645W WO 03035695 A3 WO03035695 A3 WO 03035695A3
Authority
WO
WIPO (PCT)
Prior art keywords
molecules
tlr9
bind
present
mimic
Prior art date
Application number
PCT/US2002/023645
Other languages
French (fr)
Other versions
WO2003035695A2 (en
Inventor
Ling-Ling An
Herren Wu
Michael S C Fung
Original Assignee
Tanox Inc
Ling-Ling An
Herren Wu
Michael S C Fung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanox Inc, Ling-Ling An, Herren Wu, Michael S C Fung filed Critical Tanox Inc
Priority to EP02795487A priority Critical patent/EP1412390A2/en
Priority to AU2002360243A priority patent/AU2002360243A1/en
Publication of WO2003035695A2 publication Critical patent/WO2003035695A2/en
Publication of WO2003035695A3 publication Critical patent/WO2003035695A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention includes molecules that bind to a peptidic segment on TLR9 and mimic the effects of the CpG motif. The CpG mimicking agents include, but are not limited to, antibodies, small-molecule compounds, peptides, peptide mimetics, and nucleic acids, including compositions comprising molecules that bind to a peptidic segment on TLR9 and mimic the effects of the CpG motif suitable for administering to a patient in need of treatment, optionally in combination with, for example, an excipient, diluant, or carrier. In addition, the present invention includes those molecules which bind to the TLR9's CXXC motifs at 255Cys-Arg-Arg 258Cys (as CRRC) or at 265Cys-Met-GIu 268Cys (as CMEC). The present invention includes methods for modulating the immune response by inducing a Th1-type response comprising administering molecules that bind to TLR9 and mimic CpG function. These molecules also shift the host cellular response away from a Th2-type response toward the Th1-type response. Thus, administering the molecules of the present invention that bind to TLR9 may avoid the risk of Th2-mediated, immunization-induced anaphylaxis, making this method useful in immunotherapy and asthma treatment. The molecules of the present invention may be administered in combination with a particular allergen.
PCT/US2002/023645 2001-07-26 2002-07-25 Agents that activate or inhibit toll-like receptor 9 WO2003035695A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP02795487A EP1412390A2 (en) 2001-07-26 2002-07-25 Agents that activate or inhibit toll-like receptor 9
AU2002360243A AU2002360243A1 (en) 2001-07-26 2002-07-25 Agents that activate or inhibit toll-like receptor 9

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30806801P 2001-07-26 2001-07-26
US60/308,068 2001-07-26

Publications (2)

Publication Number Publication Date
WO2003035695A2 WO2003035695A2 (en) 2003-05-01
WO2003035695A3 true WO2003035695A3 (en) 2003-11-13

Family

ID=23192407

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/023645 WO2003035695A2 (en) 2001-07-26 2002-07-25 Agents that activate or inhibit toll-like receptor 9

Country Status (4)

Country Link
EP (1) EP1412390A2 (en)
CN (1) CN1642982A (en)
AU (1) AU2002360243A1 (en)
WO (1) WO2003035695A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883174B2 (en) 2009-03-25 2014-11-11 The Board Of Regents, The University Of Texas System Compositions for stimulation of mammalian innate immune resistance to pathogens

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1366077B1 (en) 2000-09-15 2011-05-25 Coley Pharmaceutical GmbH PROCESS FOR HIGH THROUGHPUT SCREENING OF CpG-BASED IMMUNO-AGONIST/ANTAGONIST
WO2003022296A1 (en) 2001-09-07 2003-03-20 The Trustees Of Boston University Method and composition for treating immune complex associated disorders
CA2528774A1 (en) * 2003-06-20 2005-01-27 Coley Pharmaceutical Gmbh Small molecule toll-like receptor (tlr) antagonists
WO2005059517A2 (en) * 2003-12-16 2005-06-30 University Of Massachusetts Toll-like receptor assays
CA2574176A1 (en) * 2004-07-20 2006-02-09 Schering Corporation Induction of apoptosis in toll-like receptor expressing tumor cells
EP1829895A1 (en) * 2006-03-03 2007-09-05 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies
US9636415B2 (en) 2006-03-03 2017-05-02 S-Target Therapeutics Gmbh Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies
CN101240271B (en) * 2006-08-28 2012-08-29 长春华普生物技术有限公司 Toll-like receptor adjustment oligonucleotide and use thereof
CN101134046B (en) * 2006-09-01 2011-10-05 中国医学科学院药物研究所 Application of TLR4 and TLR9 agonist compound in the restraint of tumour metastasis
WO2010030790A2 (en) * 2008-09-10 2010-03-18 The Texas A&M University System Methods and compositions for stimulation of mammalian innate immune resistance to pathogens
MX2011012875A (en) 2009-06-05 2012-02-28 13Therapeutics Inc Immunoregulatory peptides and emthods of use.
EP2496944A2 (en) * 2009-11-05 2012-09-12 Novartis AG Biomarkers predictive of progression of fibrosis
CN101712957B (en) * 2009-11-25 2011-11-23 中国人民解放军第三军医大学第一附属医院 Toll-like receptor 9 (TLR9) blocking agent and application thereof
FR2975600B1 (en) 2011-05-24 2013-07-05 Assist Publ Hopitaux De Paris AGENTS FOR THE TREATMENT OF TUMORS
AR095882A1 (en) 2013-04-22 2015-11-18 Hoffmann La Roche ANTIBODY COMBINATION THERAPY AGAINST HUMAN CSF-1R WITH A TLR9 AGONIST
MX2016014926A (en) 2014-05-16 2017-05-09 Ablynx Nv Improved immunoglobulin variable domains.
US11009511B2 (en) 2014-05-16 2021-05-18 Ablynx N.V. Methods for detecting and/or measuring anti-drug antibodies, in particular treatment-emergent anti-drug antibodies
WO2016044839A2 (en) 2014-09-19 2016-03-24 The Board Of Regents Of The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
WO2019066571A2 (en) 2017-09-28 2019-04-04 연세대학교 산학협력단 Method for producing myeloid-derived suppressor cells, myeloid-derived suppressor cells produced thereby, and uses thereof
US20210317454A1 (en) * 2020-04-10 2021-10-14 Idera Pharmaceuticals, Inc. Use of a tlr9 agonist in methods for treating covid-19
TWI827057B (en) * 2021-05-18 2023-12-21 中國醫藥大學 Vaccine, use thereof and cancer vaccine cocktail

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001055386A1 (en) * 2000-01-25 2001-08-02 Glaxosmithkline Toll-like receptor
WO2001093905A1 (en) * 2000-06-08 2001-12-13 Intercell Biomedizinische Forschungs- Und Entwicklungs Ag Immunostimulatory oligodeoxynucleotides
WO2002006482A1 (en) * 2000-07-19 2002-01-24 Japan Science And Technology Corporation Receptor protein specifically recognizing bacterial dna

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001055386A1 (en) * 2000-01-25 2001-08-02 Glaxosmithkline Toll-like receptor
WO2001093905A1 (en) * 2000-06-08 2001-12-13 Intercell Biomedizinische Forschungs- Und Entwicklungs Ag Immunostimulatory oligodeoxynucleotides
WO2002006482A1 (en) * 2000-07-19 2002-01-24 Japan Science And Technology Corporation Receptor protein specifically recognizing bacterial dna

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HEMMI HIROAKI ET AL: "A Toll-like receptor recognizes bacterial DNA", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 408, no. 6813, 7 December 2000 (2000-12-07), pages 740 - 745, XP002168474, ISSN: 0028-0836 *
KRIEG A M ET AL: "CpG motifs in bacterial DNA trigger direct B-cell activation.", NATURE. ENGLAND 6 APR 1995, vol. 374, no. 6522, 6 April 1995 (1995-04-06), pages 546 - 549, XP002910391, ISSN: 0028-0836 *
WAGNER H: "Bacterial CpG DNA activates immune cells to signal infectious danger.", ADVANCES IN IMMUNOLOGY. UNITED STATES 1999, vol. 73, 1999, pages 329 - 368, XP009015569, ISSN: 0065-2776 *
WAGNER HERMANN: "Toll meets bacterial CpG-DNA.", IMMUNITY, vol. 14, no. 5, May 2001 (2001-05-01), pages 499 - 502, XP002250852, ISSN: 1074-7613 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883174B2 (en) 2009-03-25 2014-11-11 The Board Of Regents, The University Of Texas System Compositions for stimulation of mammalian innate immune resistance to pathogens
US9186400B2 (en) 2009-03-25 2015-11-17 The Board Of Regents, The University Of Texas System Compositions for stimulation of mammalian innate immune resistance to pathogens
US9504742B2 (en) 2009-03-25 2016-11-29 The Board Of Regents, The University Of Texas System Compositions for stimulation of mammalian innate immune resistance to pathogens

Also Published As

Publication number Publication date
EP1412390A2 (en) 2004-04-28
WO2003035695A2 (en) 2003-05-01
AU2002360243A1 (en) 2003-05-06
CN1642982A (en) 2005-07-20

Similar Documents

Publication Publication Date Title
WO2003035695A3 (en) Agents that activate or inhibit toll-like receptor 9
HK1070078A1 (en) Wt1 modified peptide
IL125590A (en) Peptide immunogens, process for their preparation and use thereof as vaccines against allergies
EP2255826A3 (en) Neisserial vaccine compositions comprising a combination of antigens
EP0909814A3 (en) Use of protein kinases for the diagnosis and treatment of Alzheimer's disease
HUP0301789A2 (en) Recombinant anti-cd40 antibody and uses thereof
WO1999010375A3 (en) Vaccine against hpv
BG102712A (en) Mixture of recombinant vaccinia vectors as polyenv-vaccines against hiv
IL143475A0 (en) Hepatitis b virus core antigen particles and vaccines and pharmaceutical compositions containing the same
ATE375362T1 (en) TUMOR ANTIGEN PEPTIDES DERIVED FROM CYCLOPHILIN B
SE0103754L (en) Peptides from apolipoprotein B, use thereof immunization, method of diagnosis or therapeutic treatment of ischemic cardiovascular diseases, and pharmaceutical composition and vaccine containing such peptide
WO2005007673A3 (en) Immunogenic peptides
KR910002899A (en) Blood Regulatory Peptides
WO2000012535A3 (en) Neisseria meningitidis polypeptide, nucleic acid sequence and uses thereof
EP0770624A3 (en) Peptide capable of inducing immune response to human gastric cancer and agent containing it for preventing or treating human gastric cancer
WO2001058470A3 (en) Methods for enhancing the bioavailability of a drug
WO1994026903A3 (en) Human influenza virus peptides binding hla-i molecule
CA2132742A1 (en) Synthetic Peptides and Vaccines Against Parvovirus
WO2003091275A3 (en) Compositions containing anti-hiv peptides and methods of use
AU7216498A (en) Inhibitors of the urokinase receptor
WO2000052045A3 (en) Mage-3 derived immunogenic peptides presented by mhc of class ii and the use thereof
EP1028754A4 (en) Prevention of immunoreactivity by depleting or inhibiting antigen presenting cells
WO2001007479A3 (en) Fragments of cellular prion protein and methods useful in the diagnosis and treatment of prion diseases
WO2002051237A3 (en) Helicobacter proteins, nucleic acids and uses thereof
WO2004058807A3 (en) Mhc class i restricted t-cell stimulating peptides from hepatitis b virus

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002795487

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 20028188217

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2002795487

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP